Kevin Ryan just raised a $335 million fund for AlleyCorp, and he's using the moment to say what he won't do: chase the billion-dollar rounds swallowing the rest of venture capital.
Fortune reported on July 15 that AlleyCorp closed its second institutional fund at $335 million, up from the $250 million debut fund it raised in 2024, when it took outside money for the first time. For most of its history, AlleyCorp wasn't a fund at all. It was Ryan's family office, built around companies he either ran himself or handed to founders he trusted. MongoDB, Business Insider, Gilt Groupe and Zola all trace back to that model. So does DoubleClick, the ad-tech company Ryan led as CEO before Google agreed in 2007 to buy it for $3.1 billion, a deal that closed in 2008.
That's the record. It's also the lens Ryan uses to size up today's market, and he doesn't love what he sees. He told Fortune that a company like DoubleClick, if it launched now, would likely stay private for a decade instead of going public, propped up by the kind of mega-rounds that have turned OpenAI and Anthropic into fundraising machines. His verdict was blunt. Referring to the billions flowing into the two AI labs, he said flatly, "I don't think that's venture capital." He's right to draw the line. Those checks belong in a separate category from the early-stage bets that built his own track record. Lumping them into industry-wide VC deployment numbers makes seed and Series A look healthier than they are.
The Discipline Behind the Numbers
AlleyCorp's discipline shows up in the numbers. Ryan still caps most checks under $10 million, even as later-stage AI rounds routinely clear nine and ten figures. Fortune cited one recent AlleyCorp-backed company carrying a $25 million valuation on just $500,000 in revenue. That is the kind of early, awkward, unglamorous bet that rarely gets oxygen next to an OpenAI raise. It can still be venture capital at its best.
That restraint has paid off. AlleyCorp reports an all-time internal rate of return of 60% across its investments, a figure few funds of any size can match. You don't need to pretend every small fund can do that. Most can't. But Ryan's argument has force because he's not preaching thrift from the sidelines. He's pointing to a portfolio that already includes eight unicorns, including Rogo, ShopMy, Valar Atomics and Thyme Care, across healthcare, deep tech and general tech.
Transcend Therapeutics is the cleaner example. In March, Otsuka Pharmaceutical agreed to acquire the neuropsychiatric drug developer in a deal worth up to $1.2 billion. BioPharma Dive reported the terms as $700 million upfront, with as much as $525 million tied to milestones, and Pillsbury Law also noted the transaction. AlleyCorp founded Transcend in 2021. That gives Ryan a real number attached to a real company his firm built from scratch, not only a paper valuation attached to a hot category.
Scaling Without Breaking the Model
Still, AlleyCorp isn't standing still. Ryan told Fortune he's open to growing the fund further, to somewhere in the $500 million to $600 million range, through geographic expansion or a dedicated vertical team. Biotech is the obvious candidate after Transcend. That's a notable jump for a firm that operated as a private family office for most of its life and only started answering to outside limited partners in 2024.
What makes AlleyCorp worth watching isn't the fund size. It's the bet embedded in staying small on purpose while everyone else scales up. Venture capital in 2026 increasingly looks like a barbell: enormous checks into a handful of frontier AI labs on one end, and a thinner pool of firms willing to write $2 million and $5 million checks into unproven companies on the other. Ryan is building for the second group. And he's doing it with a two-decade record of actually building companies rather than just funding them.
Here's the thing. Discipline is easier to praise at $335 million than to preserve at $600 million. A venture studio that incubates its own startups depends on Ryan and his team having the bandwidth to sit inside portfolio companies, find operators and make early product calls before the market has decided anything. Add a biotech practice, add a second city, and that bandwidth gets stretched. AlleyCorp has bet its next fund that the model can grow without losing the part that made it work.
Also read: Dave Clark Bets His Second Act on AI Agents Running Supply Chains • OpenAI Researcher Miles Wang Wants $200 Million to Bet on Failed Drugs • Hinge's Founder Just Bet $18 Million That Swiping Is Broken
